DK3117216T3 - Fremgangsmåde til detektering af en solid tumor-cancer - Google Patents
Fremgangsmåde til detektering af en solid tumor-cancer Download PDFInfo
- Publication number
- DK3117216T3 DK3117216T3 DK15716168.8T DK15716168T DK3117216T3 DK 3117216 T3 DK3117216 T3 DK 3117216T3 DK 15716168 T DK15716168 T DK 15716168T DK 3117216 T3 DK3117216 T3 DK 3117216T3
- Authority
- DK
- Denmark
- Prior art keywords
- procedure
- detection
- solid tumor
- tumor cancer
- cancer
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57473—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving carcinoembryonic antigen, i.e. CEA
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96433—Serine endopeptidases (3.4.21)
- G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
- G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1450274 | 2014-03-11 | ||
| SE1450420 | 2014-04-04 | ||
| PCT/SE2015/050272 WO2015137870A1 (en) | 2014-03-11 | 2015-03-11 | Method for detecting a solid tumor cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3117216T3 true DK3117216T3 (da) | 2023-04-03 |
Family
ID=52829276
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15716168.8T DK3117216T3 (da) | 2014-03-11 | 2015-03-11 | Fremgangsmåde til detektering af en solid tumor-cancer |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10451626B2 (da) |
| EP (2) | EP3117216B1 (da) |
| JP (1) | JP6625061B2 (da) |
| AU (2) | AU2015230017B2 (da) |
| CA (2) | CA3134289A1 (da) |
| DK (1) | DK3117216T3 (da) |
| FI (1) | FI3117216T3 (da) |
| HK (1) | HK1231559A1 (da) |
| RU (1) | RU2720148C9 (da) |
| WO (1) | WO2015137870A1 (da) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2016012667A (es) | 2014-03-28 | 2017-01-09 | Opko Diagnostics Llc | Composiciones y metodos relacionados con el diagnostico de cancer de prostata. |
| CN107406510B (zh) | 2015-03-27 | 2022-02-18 | 欧普科诊断有限责任公司 | 前列腺抗原标准品及其用途 |
| WO2017161175A1 (en) * | 2016-03-16 | 2017-09-21 | Dana-Farber Cancer Institute, Inc. | Methods for genome characterization |
| EP3270163B1 (en) * | 2016-07-15 | 2018-09-05 | ProteoMediX AG | Method of detecting proteins in human samples and uses of such methods |
| JP7138112B2 (ja) * | 2017-02-01 | 2022-09-15 | ファディア・アクチボラゲット | 特定の特徴を有する個体において前立腺癌の存在または不存在を示すための方法 |
| WO2018144678A1 (en) * | 2017-02-03 | 2018-08-09 | The Johns Hopkins University | Mini-cancers utilization for personalized cancer drug regimens |
| RU2664706C2 (ru) * | 2017-06-02 | 2018-08-21 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский радиологический центр" Министерства здравоохранения Российской Федерации (ФГБУ "НМИРЦ" Минздрава России) | Способ прогнозирования клинического статуса рака предстательной железы |
| JP7127422B2 (ja) * | 2017-08-30 | 2022-08-30 | 東ソー株式会社 | 癌を検出する方法及び検出試薬 |
| WO2020205204A1 (en) * | 2019-04-03 | 2020-10-08 | Opko Diagnostics, Llc | Methods for the detection of prostate cancer |
| IT202000029948A1 (it) * | 2020-12-04 | 2022-06-04 | Nib Biotec S R L | Metodo per la diagnosi di tumore alla prostata in pazienti in differente fascia di età |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030219840A1 (en) | 2002-05-24 | 2003-11-27 | Mikolajczyk Stephen D. | Method of analyzing proenzyme forms of prostate specific antigen in serum to improve prostate cancer detection |
| US20050277137A1 (en) | 2003-08-15 | 2005-12-15 | University Of Pittsburgh | Diagnostic multimarker serological profiling |
| KR100830811B1 (ko) | 2006-09-18 | 2008-05-20 | 충북대학교 산학협력단 | 종양표시인자 검출용 바이오센서 |
| FR2934698B1 (fr) | 2008-08-01 | 2011-11-18 | Commissariat Energie Atomique | Procede de prediction pour le pronostic ou le diagnostic ou la reponse therapeutique d'une maladie et notamment du cancer de la prostate et dispositif permettant la mise en oeuvre du procede. |
| WO2010081240A1 (en) | 2009-01-19 | 2010-07-22 | Miraculins Inc. | Diagnostic assays for prostate cancer using psp94 and psa biomarkers |
| WO2010093939A2 (en) | 2009-02-12 | 2010-08-19 | Dana-Farber Cancer Institute, Inc. | Predicting and treating prostate cancer |
| EP2407555A1 (en) | 2010-07-14 | 2012-01-18 | Fundació Institut de Recerca Hospital Universitari Vall d'Hebron, Fundació Privada | Methods and kits for the diagnosis of prostate cancer |
| WO2012031207A2 (en) | 2010-09-03 | 2012-03-08 | Wake Forest University Health Sciences | Methods and compositions for correlating genetic markers with prostate cancer risk |
| US20120202888A1 (en) | 2010-10-08 | 2012-08-09 | The Brigham And Women's Hospital, Inc. | Biomarkers of prostate cancer and predicting mortality |
| US20120150032A1 (en) | 2010-12-13 | 2012-06-14 | Julius Gudmundsson | Sequence Variants Associated with Prostate Specific Antigen Levels |
| US20150024952A1 (en) | 2010-12-28 | 2015-01-22 | Arlet Alarcon | Molecular profiling for cancer |
| US9753043B2 (en) | 2011-12-18 | 2017-09-05 | 20/20 Genesystems, Inc. | Methods and algorithms for aiding in the detection of cancer |
| WO2013172779A2 (en) * | 2012-05-16 | 2013-11-21 | Phadia Ab | Method for indicating the presence or non-presence of prostate cancer |
| CA2891394C (en) * | 2012-11-20 | 2023-03-14 | Phadia Ab | Prognostic method for individuals with prostate cancer |
| RU2675370C2 (ru) * | 2012-11-20 | 2018-12-19 | Пхадиа Аб | Способ выявления присутствия или отсутствия агрессивного рака предстательной железы |
-
2015
- 2015-03-11 CA CA3134289A patent/CA3134289A1/en active Pending
- 2015-03-11 CA CA2940445A patent/CA2940445C/en active Active
- 2015-03-11 DK DK15716168.8T patent/DK3117216T3/da active
- 2015-03-11 RU RU2016139491A patent/RU2720148C9/ru active
- 2015-03-11 WO PCT/SE2015/050272 patent/WO2015137870A1/en active Application Filing
- 2015-03-11 FI FIEP15716168.8T patent/FI3117216T3/fi active
- 2015-03-11 JP JP2016556777A patent/JP6625061B2/ja active Active
- 2015-03-11 EP EP15716168.8A patent/EP3117216B1/en active Active
- 2015-03-11 AU AU2015230017A patent/AU2015230017B2/en active Active
- 2015-03-11 US US15/124,769 patent/US10451626B2/en active Active
- 2015-03-11 EP EP23150294.9A patent/EP4220170A3/en active Pending
-
2017
- 2017-05-23 HK HK17105195.3A patent/HK1231559A1/zh unknown
-
2021
- 2021-09-15 AU AU2021232712A patent/AU2021232712A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP6625061B2 (ja) | 2019-12-25 |
| EP3117216A1 (en) | 2017-01-18 |
| EP4220170A2 (en) | 2023-08-02 |
| RU2016139491A (ru) | 2018-04-16 |
| CA3134289A1 (en) | 2015-09-17 |
| US10451626B2 (en) | 2019-10-22 |
| US20170108501A1 (en) | 2017-04-20 |
| EP3117216B1 (en) | 2023-01-11 |
| FI3117216T3 (fi) | 2023-04-27 |
| RU2720148C9 (ru) | 2020-09-28 |
| EP4220170A3 (en) | 2023-12-13 |
| RU2720148C2 (ru) | 2020-04-24 |
| AU2021232712A1 (en) | 2021-10-14 |
| RU2016139491A3 (da) | 2018-10-15 |
| CA2940445A1 (en) | 2015-09-17 |
| JP2017508970A (ja) | 2017-03-30 |
| HK1231559A1 (zh) | 2017-12-22 |
| WO2015137870A1 (en) | 2015-09-17 |
| CA2940445C (en) | 2021-11-30 |
| AU2015230017B2 (en) | 2021-06-17 |
| AU2015230017A1 (en) | 2016-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3189082T3 (da) | Anti-pd-l1-konjugater til behandling af tumorer | |
| DK3166976T3 (da) | Anti-pd-l1-kombinationer til behandling af tumorer | |
| DK3288581T3 (da) | Fremgangsmåde til behandling af cancer | |
| DK3240801T3 (da) | Kombinationstumorimmunterapi | |
| DK3192902T3 (da) | Fremgangsmåde til fremstilling af graphenholdige viscosefibre | |
| DK3241026T3 (da) | Fremgangsmåde til absolut kvantificering af naturligt forarbejdede hla-begrænsede cancerpeptider | |
| DK3233887T3 (da) | Immunmodulatorer | |
| DK3096741T3 (da) | Fremgangsmåde til fremstillingen af hybridosomer | |
| DK3137169T3 (da) | Hæmmere af lysin-specifik demethylase-1 | |
| DK3117216T3 (da) | Fremgangsmåde til detektering af en solid tumor-cancer | |
| DK3180331T3 (da) | Polymorfer af selinexor | |
| DK3174858T3 (da) | Fremgangsmåde til fremstilling af pyrazoler | |
| DK3072835T3 (da) | Fremgangsmåde til fremføring | |
| DK3122358T3 (da) | Kombinationer af fgfr- og cmet-hæmmere til cancerbehandling | |
| DK3372584T3 (da) | Fremgangsmåde til fremstillingen af en diarylthiohydantoin-forbindelse | |
| DK3186244T3 (da) | Dioxolananaloger af uridin til behandling af cancer | |
| DK3371165T3 (da) | Btk-inhibitor til anvendelse til behandling af kræft | |
| DK3148529T3 (da) | Forbindelser til behandling af hjernecancer | |
| DK3204398T3 (da) | Fremgangsmåder til fraseparering af gemcitabin-phosphat diastereoisomerer | |
| DK3125898T3 (da) | Farmakofor til trail-induktion | |
| DK3233813T3 (da) | Fremgangsmåder til fremstilling af oxathiazin-lignende forbindelser | |
| HK1260327A1 (zh) | 檢測癌症復發的方法 | |
| GB201602210D0 (en) | Detection of cancer | |
| DK3164716T3 (da) | Fremgangsmåde til diagnosticering af neurodegenerative sygdomme | |
| DE112015002984A5 (de) | Positioniereinheit |